NVasc Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 4

NVasc General Information

Description

Developer of a biopharmaceutical company intended to focus on treating blindness. The company develops therapy that treats blindness through choroidal and retinal revascularization, specifically targeting issues in the retina and choroid, enabling the healthcare sector to help patients maintain and restore vision by improving blood flow to these tissues.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 26871 Carranza Drive
  • Mission Viejo, CA 92691
  • United States
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Vertical(s)
Corporate Office
  • 26871 Carranza Drive
  • Mission Viejo, CA 92691
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NVasc Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 04-Nov-2024 Completed Startup
3. Early Stage VC (Series A2) 01-Nov-2019 Completed Startup
2. Early Stage VC $1M $1M Completed Startup
1. University Spin-Out 01-Jan-2019 Completed Startup
To view NVasc’s complete valuation and funding history, request access »

NVasc Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-2
Series A-1
To view NVasc’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

NVasc Patents

NVasc Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026006563-A1 Long-lasting lif proteins and formulations Pending 27-Jun-2024

NVasc Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Mitsui Global Investment Venture Capital Minority
Retinal Degeneration Fund Not-For-Profit Venture Capital Minority
Kairos Ventures Venture Capital Minority
University of California, San Diego University
To view NVasc’s complete investors history, request access »

NVasc FAQs

  • When was NVasc founded?

    NVasc was founded in 2019.

  • Where is NVasc headquartered?

    NVasc is headquartered in Mission Viejo, CA.

  • What industry is NVasc in?

    NVasc’s primary industry is Drug Discovery.

  • Is NVasc a private or public company?

    NVasc is a Private company.

  • What is NVasc’s current revenue?

    The current revenue for NVasc is .

  • How much funding has NVasc raised over time?

    NVasc has raised $3M.

  • Who are NVasc’s investors?

    Mitsui Global Investment, Retinal Degeneration Fund, Kairos Ventures, and University of California, San Diego have invested in NVasc.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process